Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study

Cancer poses a significant challenge to human health due to its complex biological systems, necessitating in-depth analysis. Single-cell sequencing has become an essential tool for investigating these systems, enabling the detection of gene expression and epigenetic modifications at the single-cell level. To elucidate research trends, collaboration networks, and knowledge dissemination in this field, a bibliometric analysis was conducted using the Web of Science Core Collection database, covering publications from January 1, 2010, to December 31, 2023. The Bibliometrix package in R was used to extract and analyze key publication data, including document types, countries, institutions, authors, and keywords. Additionally, CiteSpace, VOSviewer, and the Online Analysis Platform of Literature Metrology were employed for data compilation and visualization. The analysis identified 34,074 authors from 3,129 institutions across 75 countries and regions, contributing to 5,680 publications on single-cell sequencing in cancer, published in 788 academic journals. China and the United States emerged as the leading nations in publication volume. Harvard University produced the highest number of publications (320), with Aviv Regev, affiliated with Harvard, recognized as a key contributor. Leading journals, such as Frontiers in Immunology and Nature Communications, highlight both established and emerging research areas, including the immune microenvironment and immunotherapy. Key trends and potential areas for future research include intra-tumor heterogeneity, clonal evolution, and drug delivery systems. This study provides a comprehensive overview of single-cell sequencing research in oncology, emphasizing its rapid progress, driven by technological advancements and international collaborations. Strengthening global partnerships, developing integrative analytical tools, and addressing data complexities will be crucial for advancing personalized cancer therapies and deepening insights into cancer biology.